{"id":"W2561881161","doi":"10.1056/nejmoa1601277","title":"Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis","year":2016,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":1961,"is_retracted":false,"has_abstract":true,"ca_institutions":"NeuroRx Research (Canada); McGill University; University of British Columbia","funders":"Agence Nationale de la Recherche","keywords":"Ocrelizumab; Medicine; Interferon beta-1a; Multiple sclerosis; Hazard ratio; Internal medicine; Confidence interval; Gastroenterology; Immunology; Interferon beta; Rituximab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1261491570014691,"score_gpt":0.3314055627944734,"score_spread":0.2052564057930043,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}